Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

CareEdge Ratings report predicts 400 basis points drop in brokerages' net profit due to recent regulatory changes.

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.

Revenues in the Transportation Fund underperformed their $25.0 million December consensus target by $0.17 million, or 0.7%, ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, has significantly improved its revenues and strengthened its balance sheet.

Julius Berger has reported a pre-tax profit of N29.5 billion for the full year ending December 31, 2024, as outlined ...

DFM delivered a strong result for the period ending December 31st, 2024, underscoring its position as the leading financial exchange in the region. DFM reported total revenues of Dhs632.3 million for ...

Explore Lam Research's (LRCX) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.